Brief: Sino Biopharmaceutical Says TQB3205 Pan-Kras Inhibitor Receives NMPA Clinical Trial Approval
11/03/2026 17:05
March 11 (Reuters) - Sino Biopharmaceutical Ltd 1177.HK: TQB3205 PAN-KRAS INHIBITOR RECEIVES NMPA CLINICAL TRIAL APPROVAL FOR ADVANCED MALIGNANT TUMORS Further company coverage: 1177.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sino Biopharmaceutical
See all newsHong Kong stocks end higher on pharma, tech gains
Hong Kong stocks climb, led by pharmaceutical, tech stocks
Brief: Sino Biopharmaceutical Says China's CDE Accepts NDA For TQH2722 Injection
Brief: Sino Biopharmaceutical China CDE Accepts New Drug Application For TQB2102 Injection
Sino Biopharmaceutical climbs on plan to raise stake in core unit